Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer Importance of Salvage Surgery

被引:42
作者
Hamaji, Masatsugu [1 ]
Chen, Fengshi [1 ]
Matsuo, Yukinori [2 ]
Ueki, Nami [2 ]
Hiraoka, Masahiro [2 ]
Date, Hiroshi [1 ]
机构
[1] Kyoto Univ, Grad Sch Med, Dept Thorac Surg, Kyoto 6068507, Japan
[2] Kyoto Univ, Grad Sch Med, Dept Radiat Oncol & Image Appl Therapy, Kyoto 6068507, Japan
基金
日本学术振兴会;
关键词
Non-small-cell lung cancer; Surgery; Radiotherapy; Chemotherapy; POSITRON-EMISSION-TOMOGRAPHY; RADIATION-THERAPY; ABLATIVE RADIOTHERAPY; THORACOSCOPIC LOBECTOMY; TUMOR RECURRENCE; F-18-FDG PET/CT; HIGH-RISK; RESECTION; FAILURE; OUTCOMES;
D O I
10.1097/JTO.0000000000000662
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Many efforts have been made to detect local relapse (LR) in the follow-up after stereotactic body radiotherapy (SBRT) for non-small-cell lung cancer (NSCLC) although limited data are available on its treatment and prognosis. We aimed to characterize treatment options and clarify long-term outcomes of isolated LR after SBRT for patients with clinical stage I NSCLC. Methods: We reviewed our institutional database in search of patients with isolated LR after SBRT for clinical stage I NSCLC at our institution between 1999 and 2013. Patient characteristics were compared with Mann-Whitney U test, (2) test, or Fisher's exact test as appropriate. Survival outcomes were estimated with Kaplan-Meier method. Potential prognostic factors were investigated using Cox proportional hazard model. Results: Of 308 patients undergoing SBRT for clinical stage I NSCLC, 49 patients were identified to have isolated LR. Twelve patients underwent salvage surgery, none underwent radiotherapy, and eight patients received chemotherapy, whereas 29 patients received best supportive care. No patient characteristic except operability was significantly related with patient selection for LR treatments. Five-year overall survival (OS) rate of the whole cohort was 47.9% from SBRT and 25.7% from LR. Salvage surgery was associated with improved OS after LR (p = 0.014), and 5-year OS for patients undergoing salvage surgery was 79.5% from LR. Conclusions: It was confirmed that our patient selection for salvage surgery for isolated LR was associated with favorable survival outcomes. Operability based on multidisciplinary conferences, rather than measurable patient characteristics, is essential for appropriate patient selection for salvage surgery.
引用
收藏
页码:1616 / 1624
页数:9
相关论文
共 50 条
[31]   Definition of stereotactic body radiotherapy Principles and practice for the treatment of stage I non-small cell lung cancer [J].
Guckenberger, M. ;
Andratschke, N. ;
Alheit, H. ;
Holy, R. ;
Moustakis, C. ;
Nestle, U. ;
Sauer, O. .
STRAHLENTHERAPIE UND ONKOLOGIE, 2014, 190 (01) :26-33
[32]   Nodal recurrence after stereotactic body radiotherapy for early stage non-small cell lung cancer: Incidence and proposed risk factors [J].
Wink, Krista C. J. ;
van Baardwijk, Angela ;
Troost, Esther G. C. ;
De Ruysscher, Dirk .
CANCER TREATMENT REVIEWS, 2017, 56 :8-15
[33]   Comparison of efficacy of stereotactic body radiotherapy and thoracoscopic surgery in the treatment of early-stage non-small cell lung cancer [J].
Li, Xiaoqi ;
Niu, Chunbo ;
Chen, Qizhang ;
Chen, Xiaojun .
JOURNAL OF BUON, 2020, 25 (03) :1497-1503
[34]   Impact of Enlarged Nonhypermetabolic Lymph Nodes on Outcomes After Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer [J].
Verma, Vivek ;
Schonewolf, Caitlin A. ;
Cushman, Taylor R. ;
Post, Carl M. ;
Doms, Alexandra ;
Berman, Abigail T. ;
DeVries, Matthew ;
Katz, Sharyn, I ;
Simone, Charles B., II .
CLINICAL LUNG CANCER, 2018, 19 (06) :502-510
[35]   T-Cell Receptor Profiling and Prognosis After Stereotactic Body Radiation Therapy For Stage I Non-Small-Cell Lung Cancer [J].
Wu, Lirong ;
Zhu, Jun ;
Rudqvist, Nils-Petter ;
Welsh, James ;
Lee, Percy ;
Liao, Zhongxing ;
Xu, Ting ;
Jiang, Ming ;
Zhu, Xiangzhi ;
Pan, Xuan ;
Li, Pansong ;
Zhou, Zhipeng ;
He, Xia ;
Yin, Rong ;
Feng, Jifeng .
FRONTIERS IN IMMUNOLOGY, 2021, 12
[36]   Treatment and prognosis of advanced stage non-small-cell lung cancer [J].
Ben Abdallah, F. Chermiti ;
Ben Ali, G. ;
Boudaya, M. Sadok ;
Mlika, M. ;
Chtourou, A. ;
Taktak, S. ;
Ben Kheder, A. .
REVUE DES MALADIES RESPIRATOIRES, 2014, 31 (03) :214-220
[37]   Relationship between Pretreatment FDG Uptake and Local Control after Stereotactic Body Radiotherapy in Stage I Non-small-cell Lung Cancer: The Preliminary Results [J].
Hamamoto, Yasushi ;
Sugawara, Yoshifumi ;
Inoue, Takeshi ;
Kataoka, Masaaki ;
Ochi, Takashi ;
Takahashi, Tadaaki ;
Sakai, Shinya .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (04) :543-547
[38]   Outcomes After Stereotactic Lung Radiotherapy or Wedge Resection for Stage I Non-Small-Cell Lung Cancer [J].
Grills, Inga S. ;
Mangona, Victor S. ;
Welsh, Robert ;
Chmielewski, Gary ;
McInerney, Erika ;
Martin, Shannon ;
Wloch, Jennifer ;
Ye, Hong ;
Kestin, Larry L. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (06) :928-935
[39]   A propensity-matched analysis of surgery and stereotactic body radiotherapy for early stage non-small cell lung cancer in the elderly [J].
Wang, Peng ;
Zhang, Dong ;
Guo, Xue-Guang ;
Li, Xiao-Mei ;
Du, Le-Hui ;
Sun, Bao-Jun ;
Fang, Xiang-Qun ;
Guo, Ying-Hua ;
Guo, Jun ;
An, Li ;
Qu, Ge-Ping ;
Liu, Chang-Ting .
MEDICINE, 2016, 95 (52)
[40]   Stereotactic Body Radiotherapy Using a Radiobiology-Based Regimen for Stage I Non-Small-Cell Lung Cancer [J].
Shibamoto, Yuta ;
Hashizume, Chisa ;
Baba, Fumiya ;
Ayakawa, Shiho ;
Miyakawa, Akifumi ;
Murai, Taro ;
Takaoka, Taiki ;
Hattori, Yukiko ;
Asai, Ryuji .
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (06) :960-964